Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05312892

Sympathetic Mechanisms in Obesity-Crossover Design

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.

Sponsor: Vanderbilt University Medical Center

Interventions Amlodipine Moxonidine Placebo

Updated 9 times since 2022 Last updated: Feb 26, 2026 Started: May 20, 2022 Primary completion: Dec 31, 2028 Completion: Dec 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Hypertension and Obesity and is currently actively recruiting participants. Vanderbilt University Medical Center leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Mar 2025 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 4 earlier versions

Mar 2023 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Jul 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
May 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanderbilt University Medical Center

Data source: Vanderbilt University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States